Intrinsically Disordered Proteins: Dynamics, Binding, and Function thoroughly examines and ties together the fundamental biochemical functions of intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs), including signaling, binding, and regulation, with the methodology for study and the associated pathways for drug design and therapeutic intervention. The role of new mechanistic, computational, and experimental approaches in IDP study are explored in depth, with methods for the characterization of IDP dynamics; models, simulations, and mechanisms of IDP and IDR binding; and biological and medical implications of IDP dynamics prominently featured. Written and edited by leading scientists in the field, this book explores groundbreaking areas such as ensemble descriptions of IDPs and IDRs, single-molecule studies of IDPs and IDRs, IDPs and IDRs in membraneless organelles, and molecular mechanisms of fibrillation of IDPs.

Intrinsically Disordered Proteins provides students and researchers in biochemistry, molecular biology, and applied microbiology with a comprehensive and updated discussion of the complex dynamics of IDPs and IDRs.
Table of Contents

Preface
CHAPTER 1 Introduction to intrinsically disordered proteins and regions

PART I – Methodology
CHAPTER 2 Ensemble descriptions of IDPs and IDRs: Integrating simulation and experiment
CHAPTER 3 Experimental characterization of the dynamics of IDPs and IDRs by NMR
CHAPTER 4 Single-molecule fluorescence studies of IDPs and IDRs

PART II – Molecular Mechanism
CHAPTER 5 Experimental studies of binding of intrinsically disordered proteins to their partners
CHAPTER 6 Modeling protein-protein interactions with intrinsically disordered proteins

PART III – Biology and Medicine
CHAPTER 7 IDPs and IDRs in biomolecular condensates
CHAPTER 8 Molecular mechanisms of fibrillation of IDPs
CHAPTER 9 Perspectives on drug discovery strategies based on IDPs (Contributed by IDP Pharma)
CHAPTER 10 Conclusion and future directions

Bio€quity 2019, the most important biopharmaceutical investor conference in Europe, will take place in Barcelona for the first time on May 20-21, 2019. IDP Pharma will attend The meeting and present the company to investors. Organized by BioCentury and EBD Group is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects.

Bio€quity Europe has showcased more than 800 leading European companies to thousands of investment and pharma business development professionals.

IDP Pharma will attend The BIO-Spain in Sevilla (September 25th-27th, 2018). BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (+3.000) and companies participating (+800).

IDP Pharma will attend The BIO International Convention in Boston (4-7 June 2018), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

The key benefits of attending the 2018 BIO International Convention are access to global biotech and pharma leaders, exposure to industry though-leaders, and unparalleled networking opportunities with 16,000+ attendees from 74 countries. Hope yo see you there!

IDP Pharma will attend the Annual Meeting of the American Association for Cancer Research (14 -18 Apr 2018). The Meeting will take place at McCormick Place North/South in Chicago , Illinois USA. AACR 2018, Annual Meeting of the American Association for Cancer Research is going to be dealing with Medical, Health Care, Oncology and Cancer.

IDP Pharma will attend next 11th Annual European Life Sciences CEO Forum & Exhibition. This event is being held on 26th-27th February 2018 at the Hilton Zurich Airport Hotel, Switzerland, and organized by Sachs Associates. IDP Pharma will be also one of the presenting companies.

This event will be highly transactional, bringing together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders. It is expected over 350 delegates and 70+ presenting companies. Event’s networking will be powered by online One-2-One meeting system and dedicated meeting facilities to make the event more transactional and productive. We hope to see you there!

IDP Pharma and BCN Peptides engage in the development of a new chemical entity aimed to treat Multiple Myeloma. The collaborative project has been granted with funds from the European Union FEDER via ACCIO and its programme «Nuclis d’Innovació Tecnológica».

IDP Pharma will attend next BIO-Europe spring, Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. It is regarded as a “must attend” event for the biotech industry. This event will take place in Barcelona from 20-22 March 2017.

IDP Pharma has closed a 1,4M€ seed investment round, following a pre-seed round of 0,1M€ (June 2015) , which adds to the 1,2M€ funds granted by several public institutions (MINECO, ENISA, CDTI-NEOTEC and ACCIÓ).

The company will allocate the capital to advance the preclinical development of its first products for two cancer indications, to set up new discovery programs, and to continue developing its technology: IDP-Platform.

IDP Pharma will attend next Bio International Convention 2016 in San Francisco, the world’s largest biotechnology event. The BIO attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. You will find partnering opportunities, an outstanding education program, an expansive exhibition floor, and exclusive networking events where you will access over 2,500 CEO’s from leading biotech companies.

IDP Pharma has closed its first investment round. The funds raised will allow the company to develop its technology and deliver first active compounds against an IDP, a novel class of therapeutic targets.

IDP Pharma has stablished its headquarters at the Parc Científic de Barcelona (PCB).

The Parc Científic de Barcelona offers institutions and companies an ideal environment dedicated to the generation, transfer and addition of value in the field of the life sciences, with state-of-the-art facilities for drug discovery.